Abstract:Lactate is the primary tumor immunosuppressive factor limiting the effectiveness of tumor treatment. The authors develop a secure biocatalytic immunoenhancement strategy to boost antitumor immunity by consuming intratumoral lactate and inducing metabolic reprogramming using a nanoreactor. Through the design of this delicate catalytic immunoenhancement strategy, nanoreactors with lactate as a target may open a promising and secure avenue for tumor therapy. Lactate, a characteristic metabolite of the tumor microenvironment (TME), drives immunosuppression and promotes tumor progression. Material‐engineered strategies for intratumoral lactate modulations demonstrate their promise for tumor immunotherapy. However, understanding of the inherent interconnections of material‐enabled lactate regulation, metabolism, and immunity in the TME is scarce. To address this issue, urchin‐like catalysts of the encapsulated Gd‐doped CeO2, syrosingopine, and lactate oxidase are used in ZIF‐8 (USL, where U, S, and L represent the urchin‐like Gd‐doped CeO2@ZIF‐8, syrosingopine, and lactate oxidase, respectively) and orthotopic tumor models. The instructive relationships of intratumoral lactate depletion, metabolic reprogramming, and immune activation for catalytic immunotherapy of tumors is illustrated. The catalysts efficiently oxidize intratumoral lactate and significantly promote tumor cell apoptosis by in situ‐generated ·OH, thereby reducing glucose supply and inducing mitochondrial damage via lactate depletion, thus reprogramming glycometabolism. Subsequently, such catalytic metabolic reprogramming evokes both local and systemic antitumor immunity by activating M1‐polarizaed macrophages and CD8+ T cells, leading to potent antitumor immunity. This study provides valuable mechanistic insights into material‐interfered tumor therapy through intratumoral lactate depletion and consequential connection with metabolic reprogramming and immunity remodeling, which is thought to enhance the efficacy of immunotherapy.

Supercharging cancer-fighting T cells with lithium carbonate

Lithium carbonate revitalizes tumor-reactive CD8 + T cells by shunting lactic acid into mitochondria

Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity

Lactate in the tumor microenvironment: A rising star for targeted tumor therapy

Lactate oxidase nanocapsules boost T cell immunity and efficacy of cancer immunotherapy

Lactate Exposure Promotes Immunosuppressive Phenotypes in Innate Immune Cells

Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight

How lactate affects immune strategies in lymphoma

Lithium: A Promising Anticancer Agent

Insights into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral Activity

Restricting tumor lactic acid metabolism using dichloroacetate improves T cell functions

Lactate metabolic pathway regulates tumor cell metastasis and its use as a new therapeutic target

Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8+ cytolytic T cells

Tumor‐Selective Nano‐Dispatcher Enforced Cancer Immunotherapeutic Effects via Regulating Lactate Metabolism and Activating Toll‐Like Receptors

A Sub-6 Nm MnFe2O4-dichloroacetic Acid Nanocomposite Modulates Tumor Metabolism and Catabolism for Reversing Tumor Immunosuppressive Microenvironment and Boosting Immunotherapy.

Tumor Microenvironment: Lactic Acid Promotes Tumor Development

High Lactate‐Metabolizing Photosynthetic Bacteria Reprogram Tumor Immune Microenvironment

Ultrastructural Changes in Hepatocellular Carcinoma-29 Cells after Treatment with Lithium Carbonate

Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer

Current Advances on Nanomaterials Interfering with Lactate Metabolism for Tumor Therapy

Polyphenol nanocomplex modulats lactate metabolic reprogramming and elicits immune responses to enhance cancer therapeutic effect